DEF: DarioHealth Proxy: Governance, Equity, and Financing Votes

DarioHealth Corp. calls its Annual Meeting for January 29, 2026, to vote on director re-elections, auditor ratification, prior equity issuances, an expanded incentive plan, executive compensation, and a charter amendment.

Summary

• The Annual Meeting of Stockholders will be held on Thursday, January 29, 2026, at 4:00 p.m. (Israel Time) at the company's Israel office.
• The record date for stockholders entitled to vote is December 22, 2025, with 6,758,412 shares of Common Stock outstanding.
• Stockholders will vote on the re-election of seven directors: Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Lawrence Leisure, and Adam K. Stern.
• The appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is up for ratification.
• Ratification is sought for the conversion of 25,605 shares of Series D Preferred Stock into 1,697,843 shares of Common Stock, the issuance of up to 679,137 Common Stock as dividends, and up to 208,754 Common Stock under lock-up agreements, all stemming from private placement transactions in December 2024 and January 2025.
• Ratification is also requested for the issuance of Common Stock upon the exercise of pre-funded warrants, warrants, and restricted stock units related to the acquisition of Twill Inc. on February 15, 2024.
• A proposal to amend the 2020 Equity Incentive Plan to increase the number of shares authorized for issuance by 500,000 shares, bringing the total to 1,394,883, will be voted upon.
• A non-binding advisory resolution regarding the compensation of the company's named executive officers ('Say on Pay') is included.
• An amendment to the company's Certificate of Incorporation is proposed to grant the Board the right to amend the company's bylaws.
• All share and price per share information reflects a 20-for-1 reverse stock split effected on August 28, 2025.

Sentiment

Score: 3

Explanation: The filing highlights significant corporate governance issues requiring ratification of past equity issuances due to quorum uncertainty, coupled with a substantial decline in Total Shareholder Return (TSR) and a large increase in executive compensation despite ongoing net losses. While the net loss improved, the overall picture suggests operational challenges and potential shareholder value erosion.

Positives

• The Board unanimously recommends a vote FOR all proposals, indicating internal alignment on strategic and governance matters.
• The proposed increase of 500,000 shares in the 2020 Equity Incentive Plan aims to enhance the company's ability to attract, motivate, and retain qualified employees, directors, and consultants, and to preserve cash by issuing equity in lieu of cash payments.
• The net loss decreased by 28.1% from $(59,427,000) in 2023 to $(42,747,000) in 2024, primarily due to an increase in gross profit.

Negatives

• The company is seeking ratification for prior equity issuances (Private Placement and Twill acquisition) due to uncertainty regarding the quorum threshold (33 1/3% vs. majority) at previous stockholder meetings, suggesting potential governance oversight issues.
• Total Shareholder Return (TSR) decreased significantly by approximately 54.30% from an initial $100 investment to $45.70 from 2023 to 2024.
• Compensation actually paid to the Chief Executive Officer increased by approximately 512% from $274,283 in 2023 to $1,678,609 in 2024, despite the negative TSR.
• Compensation actually paid to other Named Executive Officers increased by approximately 557% from $576,066 in 2023 to $3,782,931 in 2024, also despite the negative TSR.
• The company reported a net loss of $(42,747,000) in 2024, continuing a trend of unprofitability.

Risks

• Failure to ratify the Private Placement Proposal could lead to Nasdaq non-compliance, resulting in potential additional conditions, public reprimand, suspension of trading, or delisting of the Common Stock.
• Failure to ratify the Nasdaq Rule 5635 Proposal (related to the Twill Inc. acquisition) carries similar risks of Nasdaq non-compliance, public reprimand, trading suspension, or delisting.
• The increase in shares authorized for the 2020 Equity Incentive Plan may dilute the earnings per share, book value per share, stock ownership, and voting rights of existing stockholders.
• The effective increase in authorized but unissued shares under the incentive plan could be construed as having an anti-takeover effect.
• There is a risk of adverse tax consequences for participants if equity awards do not satisfy the conditions of Section 409A of the Code.

Future Outlook

The company intends to use the increased share reserve under the 2020 Equity Incentive Plan to attract, motivate, and retain qualified employees, directors, and consultants, and to preserve cash by issuing equity in lieu of cash payments. This is part of a broader strategy to ramp up its business-to-business-to-consumer go-to-market approach in the coming fiscal years.

Management Comments

• Our Board unanimously recommends that the stockholders vote FOR all proposals being put before our stockholders at the Meeting.
• Our management believes that Proposals 2 and 7 are routine matters for which brokers, bank or other nominees will have authority to vote your shares at the Meeting if you do not give instruction on how to vote your shares.
• The Board values the opinions expressed by the stockholders in this advisory vote and will consider the outcome of this vote in determining its compensation policies.
• The Board believes that having such authority to amend the bylaws without stockholder approval provides it with important flexibility to make amendments to the bylaws that the Board believes is in the best interests of the corporation and its stockholders.

Industry Context

The company operates in the digital health and biotech sectors, as evidenced by the acquisition of Twill Inc. and the professional backgrounds of its directors, which include venture capital in biotech, health insurance, and medical device industries. The expansion of the equity incentive plan and the stated focus on a business-to-business-to-consumer (B2B2C) go-to-market strategy align with broader industry trends in digital health to attract and retain specialized talent and scale operations through strategic partnerships and market penetration.

Comparison to Industry Standards

• The necessity to ratify previously approved equity issuances due to quorum uncertainty at prior meetings is a deviation from robust corporate governance standards, which typically ensure clear and unambiguous shareholder approvals.
• The significant increase in executive compensation (CEO +512%, other NEOs +557%) in 2024, juxtaposed with a substantial decline in Total Shareholder Return (TSR) of 54.30% over the same period, indicates a misalignment with common industry best practices for pay-for-performance.
• The proposal to grant the Board the right to amend bylaws without stockholder approval, while permissible under Delaware law and common among many public companies, can be viewed as a reduction in direct shareholder oversight compared to more shareholder-centric governance models.
• The expansion of the equity incentive plan is a standard tool for talent retention and motivation in growth-oriented industries like digital health, aligning with common practices to incentivize performance.

Management Changes

Corporate Governance

Related Party Transactions

• Lawrence Leisure, a director, is Co-Founder and Co-Managing Partner of Chicago Pacific Founders and has an interest in NearWater Growth, LLC. NearWater provides investment and business consulting services to the company and receives a monthly cash retainer and equity compensation (approximately 12,900 shares of Common Stock and warrants to purchase up to 6,250 shares) if certain milestones are met.
• Adam Stern, a director, was nominated to the Board pursuant to a placement agency agreement with Aegis Capital Corp., where he serves as head of Private Equity Banking and CEO of SternAegis Ventures.

Stakeholder Impact

• Shareholders face potential dilution from the expanded equity incentive plan and prior equity issuances. There is a risk of delisting if the ratification proposals are not approved. The proposed charter amendment could alter the balance of power between the Board and stockholders regarding bylaw amendments. Shareholders have experienced a significant decline in Total Shareholder Return.
• Employees and management stand to benefit from the expanded equity incentive plan, which aims to attract and retain talent. Executive compensation saw a substantial increase in 2024.
• Creditors and investors benefit from the capital raised through the private placement. Ratification of past equity issuances is crucial for maintaining compliance with Nasdaq rules, which is important for market access and investor confidence.

Next Steps

• Hold the Annual Meeting of Stockholders on January 29, 2026, to vote on all proposed matters.
• If approved, file the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware.
• The Board will consider the outcome of the non-binding 'Say on Pay' advisory vote when making future executive compensation decisions.
• Announce preliminary voting results at the Meeting and file a Current Report on Form 8-K announcing the final voting results.

Key Dates

Recommendation

While the company shows an improvement in net loss and is taking steps to address governance and talent retention, the significant decline in Total Shareholder Return (TSR) coupled with a substantial increase in executive compensation raises concerns about shareholder value alignment. The need to ratify prior equity issuances due to quorum uncertainty also points to potential operational or governance weaknesses. The proposed actions are largely procedural or aimed at future growth, but the past performance and governance issues suggest a 'hold' position until clearer signs of sustained financial improvement and stronger shareholder alignment emerge.

Keywords

DarioHealth, DRIO, Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Auditor Ratification, Private Placement, Equity Incentive Plan, Executive Compensation, Nasdaq Compliance, Stock Split, Twill Acquisition, Shareholder Vote